Guidance on vaccination of HIV-infected children in Europe

HIV Medicine

Volumn 13, Issue 6, 2012, Pages 333-336

  Menson, E N ^a   Mellado, M J ^b   Bamford, A ^c   Castelli, G ^d   Duiculescu, D ^e   Marczynska M ^f   Navarro, M L ^g   Scherpbier, H J ^h   Heath, P T ⁱ  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d Infectious Diseases Paediatric Unit   (Italy)

^e VICTOR BABES NATIONAL INSTITUTE OF PATHOLOGY   (Romania)

^f MEDICAL UNIVERSITY OF WARSAW   (Poland)

^g HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^h EMMA CHILDREN S HOSPITAL   (Netherlands)

ⁱ ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Europe; Guideline; HIV; Immunization; Paediatric

Indexed keywords

ANTIRETROVIRUS AGENT; BCG VACCINE; DIPHTHERIA PERTUSSIS TETANUS HEPATITIS B VACCINE; DIPHTHERIA TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; ROTAVIRUS VACCINE; TETANUS ANTIBODY; VARICELLA ZOSTER VACCINE; WART VIRUS VACCINE;

ANTIBIOTIC PROPHYLAXIS; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BCG VACCINATION; BOVINE TUBERCULOSIS; CELLULAR IMMUNITY; DIPHTHERIA; DRUG EFFICACY; EUROPE; HAEMOPHILUS INFLUENZAE TYPE B; HEPATITIS A; HEPATITIS B; HERPES ZOSTER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOCOMPROMISED PATIENT; INFLUENZA; MEASLES; MEASLES VIRUS; MENINGOCOCCOSIS; MUMPS; MUMPS VIRUS; MYCOBACTERIUM BOVIS; PERTUSSIS; PNEUMOCOCCAL INFECTION; POLIOMYELITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVACCINATION; ROTAVIRUS; ROTAVIRUS INFECTION; RUBELLA; RUBELLA VIRUS; STREPTOCOCCUS PNEUMONIAE; TETANUS; TREATMENT RESPONSE; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; VACCINATION; VARICELLA ZOSTER VIRUS; VERRUCA VULGARIS; VIRUS LOAD;

ADOLESCENT; ANTIBODIES, VIRAL; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BACTERIAL VACCINES; CHILD; CHILD, PRESCHOOL; EUROPE; FEMALE; HIV SEROPOSITIVITY; HIV-1; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; IMMUNOCOMPROMISED HOST; INFANT; LONGITUDINAL STUDIES; MALE; TIME FACTORS; VACCINATION; VIRAL VACCINES; VIRUS REPLICATION;

EID: 84861803433     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2011.00982.x     Document Type: Article

References (117)

1. Gibb DM, Duong T, Tookey PA etal. Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland. BMJ 2003; 327: 1019.
2. Sanchez JM, Ramos Amador JT, Fernandez de Miguel S etal. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children. Pediatr Infect Dis J 2003; 22: 863-867.
3. de Martino M, Tovo PA, Balducci M etal. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry. JAMA 2000; 284: 190-197.
4. Obaro SK, Pugatch D, Luzuriaga K. Immunogenicity and efficacy of childhood vaccines in HIV-1-infected children. Lancet Infect Dis 2004; 4: 510-518.
5. Moss WJ, Clements CJ, Halsey NA. Immunization of children at risk of infection with human immunodeficiency virus. Bull World Health Organ 2003; 81: 61-70.
6. Vigano A, Vella S, Saresella M etal. Early immune reconstitution after potent antiretroviral therapy in HIV-infected children correlates with the increase in thymus volume. AIDS 2000; 14: 251-261.
7. Gibb DM, Newberry A, Klein N etal. Immune repopulation after HAART in previously untreated HIV-1-infected children. Paediatric European Network for Treatment of AIDS (PENTA) Steering Committee. Lancet 2000; 355: 1331-1332.
8. Borkowsky W, Stanley K, Douglas SD etal. Immunologic response to combination nucleoside analogue plus protease inhibitor therapy in stable antiretroviral therapy-experienced human immunodeficiency virus-infected children. J Infect Dis 2000; 182: 96-103.
9. Sutcliffe CG, Moss WJ. Do children infected with HIV receiving HAART need to be revaccinated? Lancet Infect Dis 2010; 10: 630-642.
10. Tejiokem MC, Gouandjika I, Beniguel L etal. HIV-infected children living in Central Africa have low persistence of antibodies to vaccines used in the Expanded Program on Immunization. PLoS ONE 2007; 2: e1260.
11. Hesseling AC, Cotton MF, Fordham von Reyn C etal. Consensus statement on the revised World Health Organization recommendations for BCG vaccination in HIV-infected infants. Int J Tuberc Lung Dis 2008; 12: 1376-1379.
12. Mansoor N, Scriba TJ, de Kock M etal. HIV-1 infection in infants severely impairs the immune response induced by Bacille Calmette-Guerin vaccine. J Infect Dis 2009; 199: 982-990.
13. Helfand RF, Witte D, Fowlkes A etal. Evaluation of the immune response to a 2-dose measles vaccination schedule administered at 6 and 9 months of age to HIV-infected and HIV-uninfected children in Malawi. J Infect Dis 2008; 198: 1457-1465.
14. Traggiai E, Puzone R, Lanzavecchia A. Antigen dependent and independent mechanisms that sustain serum antibody levels. Vaccine 2003; 21 (SUPPL 2): S35-S37.
15. Ramilo O, Hicks PJ, Borvak J etal. T cell activation and human immunodeficiency virus replication after influenza immunization of infected children. Pediatr Infect Dis J 1996; 15: 197-203.
16. Goetz MB, Feikin DR, Lennox JL etal. Viral load response to a pneumococcal conjugate vaccine, polysaccharide vaccine or placebo among HIV-infected patients. AIDS 2002; 16: 1421-1423.
17. Rosenblatt HM, Song LY, Nachman SA etal. Tetanus immunity after diphtheria, tetanus toxoids, and acellular pertussis vaccination in children with clinically stable HIV infection. J Allergy Clin Immunol 2005; 116: 698-703.
18. Stanley SK, Ostrowski MA, Justement JS etal. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med 1996; 334: 1222-1230.
19. Sullivan PS, Hanson DL, Dworkin MS etal. Effect of influenza vaccination on disease progression among HIV-infected persons. AIDS 2000; 14: 2781-2785.
20. Myers C, Posfay-Barbe KM, Aebi C etal. Determinants of vaccine immunity in the cohort of human immunodeficiency virus-infected children living in Switzerland. Pediatr Infect Dis J 2009; 28: 996-1001.
21. Fernandez-Ibieta M, Ramos-Amador JT, Aunon-Martin I. HIV-infected children vaccination coverage and safety in a Western European cohort: a retrospective study. Int J STD AIDS 2007; 18: 351-353.
22. Bamford A, Cunnington A, Daniel J etal. Immunisation status of children with HIV: failure to protect a vulnerable population. 27th Annual Meeting of the European Society for Paediatric Infectious Disease. Brussels, Belgium, June 2009. Pediatr Infect Dis J 2009; 28: e79 [Abstract P227].
23. Geretti AM, Brook G, Cameron C etal. British HIV Association guidelines for immunization of HIV-infected adults 2008. HIV Med 2008; 9: 795-848.
24. Mofenson LM, Brady MT, Danner SP etal. Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep 2009; 58: 1-166.
25. World Health Organization. Catalogue of immunization policy recommendations. Available at: (accessed February 2011).
26. Health Council of the Netherlands. General Vaccination against Hepatitis B Revisited. The Hague, Health Council of the Netherlands, 2009: publication no. 2009/03E. ISBN 978-90-5549-764-5.
27. Pensieroso S, Cagigi A, Palma P etal. Timing of HAART defines the integrity of memory B cells and the longevity of humoral responses in HIV-1 vertically-infected children. Proc Natl Acad Sci U S A 2009; 106: 7939-7944.
28. Ho Tsong Fang R, Colantonio AD, Uittenbogaart CH. The role of the thymus in HIV infection: a 10 year perspective. AIDS 2008; 22: 171-184.
29. Moore RD, Keruly JC. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis 2007; 44: 441-446.
30. Abzug MJ, Warshaw M, Rosenblatt HM etal. Immunogenicity and immunologic memory after hepatitis B virus booster vaccination in HIV-infected children receiving highly active antiretroviral therapy. J Infect Dis 2009; 200: 935-946.
31. Farquhar C, Wamalwa D, Selig S etal. Immune responses to measles and tetanus vaccines among Kenyan human immunodeficiency virus type 1 (HIV-1)-infected children pre- and post-highly active antiretroviral therapy and revaccination. Pediatr Infect Dis J 2009; 28: 295-299.
32. Rigaud M, Borkowsky W, Muresan P etal. Impaired immunity to recall antigens and neoantigens in severely immunocompromised children and adolescents during the first year of effective highly active antiretroviral therapy. J Infect Dis 2008; 198: 1123-1130.
33. Bekker V, Scherpbier H, Pajkrt D etal. Persistent humoral immune defect in highly active antiretroviral therapy-treated children with HIV-1 infection: loss of specific antibodies against attenuated vaccine strains and natural viral infection. Pediatrics 2006; 118: e315-e322.
34. Abzug MJ, Song L-Y, Fenton T etal. Pertussis booster vaccination in HIV-infected children receiving highly active antiretroviral therapy. Pediatrics 2007; 120: e1190-e1202.
35. Weinberg A, Pahwa S, Oyomopito R etal. Antimicrobial-specific cell-mediated immune reconstitution in children with advanced human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis 2004; 39: 107-114.
36. Hardy GA, Imami N, Sullivan AK etal. Reconstitution of CD4+ T cell responses in HIV-1 infected individuals initiating highly active antiretroviral therapy (HAART) is associated with renewed interleukin-2 production and responsiveness. Clin Exp Immunol 2003; 134: 98-106.
37. Zaccarelli-Filho CA, Ono E, Machado DM etal. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression. Cytometry B Clin Cytom 2007; 72: 14-21.
38. Volk VK, Gottshall RY, Anderson HD etal. Antigenic response to booster dose of diphtheria and tetanus toxoids. Seven to thirteen years after primary inoculation of noninstitutionalized children. Public Health Rep 1962; 77: 185-194.
39. de Martino M, Podda A, Galli L etal. Acellular pertussis vaccine in children with perinatal human immunodeficiency virus-type 1 infection. Vaccine 1997; 15: 1235-1238.
40. Salisbury D, Ramsay M, Noakes K. Immunisation against Infectious Disease. Norwich, TSO, 2006.
41. Schmitz V, Florkin B, Lepage P. Reactogenicity and immunogenicity of a meningococcal group C conjugate vaccine in HIV-infected children. Program and abstracts of the 43rd Annual ICAAC. Chicago, Illinois, September 2003 [Abstract D1860. G1646].
42. Centers for Disease Control and Prevention (CDC). Revised recommendations of the Advisory Committee on Immunization Practices to vaccinate all persons aged 11-18 years with meningococcal conjugate vaccine. MMWR Morb Mortal Wkly Rep 2007; 56: 794-795.
43. Centers for Disease Control and Prevention. Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for revaccination of persons at prolonged increased risk for meningococcal disease. MMWR Morb Mortal Wkly Rep 2009; 58: 1042-1043.
44. Centers for Disease Control and Prevention. Notice to readers: recommendation from the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent Meningococcal Conjugate Vaccine (MCV4) in children aged 2-10 years at increased risk for invasive meningococcal disease. MMWR Morb Mortal Wkly Rep 2007; 55: 1265-1266.
45. Donnelly J, Medini D, Boccadifuoco G etal. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A 2010; 107: 19490-19495.
46. Bliss SJ, O'Brien KL, Janoff EN etal. The evidence for using conjugate vaccines to protect HIV-infected children against pneumococcal disease. Lancet Infect Dis 2008; 8: 67-80.
47. Hartwig NG, Rumke HC. Two pneumococcal vaccines: the 7-valent conjugate vaccine (Prevenar) for children up to the age of 5 years and the 23-valent polysaccharide vaccine (Pneumo 23) for the elderly and specific groups at risk. Ned Tijdschr Geneeskd 2007; 151: 2592.
48. American Academy of Pediatrics Committee on Infectious Diseases. Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23). Pediatrics 2010; 126: 186-190.
49. Russell FM, Carapetis JR, Balloch A etal. Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months of age, a randomized controlled trial. Vaccine 2010; 28: 3341-3349.
50. Russell FM, Carapetis JR, Burton RL etal. Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age. Vaccine 2011; 29: 535-544.
51. Mangtani P, Mulholland K, Madhi SA etal. Haemophilus influenzae type b disease in HIV-infected children: a review of the disease epidemiology and effectiveness of Hib conjugate vaccines. Vaccine 2010; 28: 1677-1683.
52. Kapogiannis BG, Soe MM, Nesheim SR etal. Trends in bacteremia in the pre- and post-highly active antiretroviral therapy era among HIV-infected children in the US perinatal AIDS Collaborative Transmission Study (1986-2004). Pediatrics 2008; 121: e1229-e1239.
53. Gibb D, Spoulou V, Giacomelli A etal. Antibody responses to haemophilus influenzae type b and Streptococcus pneumoniae vaccines in children with human immunodeficiency virus infection. Pediatr Infect Dis J 1995; 14: 129-135.
54. Melvin AJ, Mohan KM. Response to immunization with measles, tetanus, and Haemophilus influenzae type b vaccines in children who have human immunodeficiency virus type 1 infection and are treated with highly active antiretroviral therapy. Pediatrics 2003; 111: e641-e644.
55. Serpe JN, Schmitz V, Lepage P. Vaccinations in HIV-infected children. Rev Med Liege 2005; 60: 923-930.
56. Centers for Disease Control and Prevention. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding routine poliovirus vaccination. MMWR Morb Mortal Wkly Rep 2009; 58: 829-830.
57. Geretti AM, Doyle T. Immunization for HIV-positive individuals. Curr Opin Infect Dis 2010; 23: 32-38.
58. Kaic B, Gjenero-Margan I, Kurecic-Filipovic S, Muscat M. A measles outbreak in Croatia, 2008. Euro Surveill 2009; 14: 1-3.
59. Schmid D, Kasper S, Kuo HW etal. Ongoing rubella outbreak in Austria, 2008-2009. Euro Surveill 2009; 14: 1-3.
60. Health Protection Agency, Health Protection Report. Mumps increase in university students. 2009. Available at: (accessed May 2011).
61. Global Advisory Committee on Vaccine Safety. Report of meeting held 17-18 June 2009. Wkly Epidemiol Rec 2009; 84: 325-332.
62. Welch S, Sharland M, Lyall E etal. PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. HIV Med 2009; 10: 591-613.
63. Jong EC, Freedman DO. The immunocompromised traveler. Centers for Disease Control and Prevention, ed. CDC Health Information for International Travel 2010. Atlanta, U.S. Department of Health and Human Services, Public Health Service, 2009: 522.
64. Aurpibul L, Puthanakit T, Sirisanthana T, Sirisanthana V. Response to measles, mumps, and rubella revaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy. Clin Infect Dis 2007; 45: 637-642.
65. Levin MJ, Gershon AA, Weinberg A etal. Immunization of HIV-infected children with varicella vaccine. J Pediatr 2001; 139: 305-310.
66. Asano Y, Nagai T, Miyata T etal. Long-term protective immunity of recipients of the OKA strain of live varicella vaccine. Pediatrics 1985; 75: 667-671.
67. Levin MJ, Gershon AA, Weinberg A etal. Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4(+) T cells. J Infect Dis 2006; 194: 247-255.
68. Son M, Shapiro ED, LaRussa P etal. Effectiveness of varicella vaccine in children infected with HIV. J Infect Dis 2010; 201: 1806-1810.
69. Marin M, Guris D, Chaves SS etal. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56: 1-40.
70. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention. MMWR Recomm Rep 1996; 45: 1-36.
71. Centers for Disease Control and Prevention. Varicella-zoster immune globulin for the prevention of chickenpox. MMWR Morb Mortal Wkly Rep 1984; 33: 84-90.
72. Harriman K, Chavez G. Varicella (Chickenpox). Centers for Disease Control and Prevention, ed. CDC Health Information for International Travel 2010. Atlanta, U.S. Department of Health and Human Services, Public Health Service, 2009: 326.
73. Siriaksorn S, Puthanakit T, Sirisanthana T, Sirisanthana V. Prevalence of protective antibody against hepatitis B virus in HIV-infected children with immune recovery after highly active antiretroviral therapy. Vaccine 2006; 24: 3095-3099.
74. Lao-araya M, Puthanakit T, Aurpibul L, Sirisanthana T, Sirisanthana V. Antibody response to hepatitis B re-vaccination in HIV-infected children with immune recovery on highly active antiretroviral therapy. Vaccine 2007; 25: 5324-5329.
75. Simani OE, Leroux-Roels G, Francois G etal. Reduced detection and levels of protective antibodies to hepatitis B vaccine in under 2-year-old HIV positive South African children at a paediatric outpatient clinic. Vaccine 2009; 27: 146-151.
76. Scolfaro C, Fiammengo P, Balbo L, Madon E, Tovo PA. Hepatitis B vaccination in HIV-1-infected children: double efficacy doubling the paediatric dose. AIDS 1996; 10: 1169-1170.
77. Jongjirawisan Y, Ungulkraiwit P, Sungkanuparph S. Isolated antibody to hepatitis B core antigen in HIV-1 infected patients and a pilot study of vaccination to determine the anamnestic response. J Med Assoc Thai 2006; 89: 2028-2034.
78. Centers for Disease Control and Prevention. Hepatitis A vaccination coverage among children aged 24-35 months - United States, 2004-2005. MMWR Morb Mortal Wkly Rep 2007; 56: 678-681.
79. Weinberg A, Gona P, Nachman SA etal. Antibody responses to hepatitis A virus vaccine in HIV-infected children with evidence of immunologic reconstitution while receiving highly active antiretroviral therapy. J Infect Dis 2006; 193: 302-311.
80. Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55: 1-23.
81. Montoya CJ, Toro MF, Aguirre C etal. Abnormal humoral immune response to influenza vaccination in pediatric type-1 human immunodeficiency virus infected patients receiving highly active antiretroviral therapy. Mem Inst Oswaldo Cruz 2007; 102: 501-508.
82. Hancock K, Veguilla V, Lu X etal. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009; 361: 1945-1952.
83. Esposito S, Tagliaferri L, Daleno C etal. Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents. Vaccine 2011; 29: 1677-1682.
84. World Health Organization. Recommendations for influenza vaccines. Available at (accessed May 2011).
85. Ambrose CS, Walker RE, Connor EM. Live attenuated influenza vaccine in children. Semin Pediatr Infect Dis 2006; 17: 206-212.
86. King JC Jr, Fast PE, Zangwill KM etal. Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children. Pediatr Infect Dis J 2001; 20: 1124-1131.
87. Levin MJ, Song LY, Fenton T etal. Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children. Vaccine 2008; 26: 4210-4217.
88. Kiulia NM, Nyaundi JK, Peenze I etal. Rotavirus infections among HIV-infected children in Nairobi, Kenya. J Trop Pediatr 2009; 55: 318-323.
89. Steele AD, Cunliffe N, Tumbo J etal. A review of rotavirus infection in and vaccination of human immunodeficiency virus-infected children. J Infect Dis 2009; 200 (SUPPL 1): S57-S62.
90. Steele AD, Madhi SA, Louw CE etal. Safety, reactogenicity, and immunogenicity of human rotavirus vaccine RIX4414 in human immunodeficiency virus-positive infants in South Africa. Pediatr Infect Dis J 2011; 30: 125-130.
91. Clifford GM, Goncalves MA, Franceschi S, HPV and HIV Study Group. Human papillomavirus types among women infected with HIV: a meta-analysis. AIDS 2006; 20: 2337-2344.
92. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000; 92: 1500-1510.
93. Smith JS, Lindsay L, Hoots B etal. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007; 121: 621-632.
94. Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 1915-1927.
95. Paavonen J, Naud P, Salmeron J etal. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374: 301-314.
96. Kroger AT, Atkinson WL, Marcuse EK etal. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55: 1-48.
97. Markowitz LE, Dunne EF, Saraiya M etal. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56: 1-24.
98. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007; 13: 28-41.
99. May J. HPV vaccination - a paradigm shift in public health. Aust Fam Physician 2007; 36: 106-111.
100. World Health Organization. Revised BCG vaccination guidelines for infants at risk for HIV infection. Wkly Epidemiol Rec 2007; 82: 193-196.
101. Bannister C, Bennett L, Carville A, Azzopardi P. Evidence behind the WHO guidelines: hospital care for children: what is the evidence that BCG vaccination should not be used in HIV-infected children? J Trop Pediatr 2009; 55: 78-82.
102. Bhadelia N, Klotman M, Caplivski D. The HIV-positive traveler. Am J Med 2007; 120: 574-580.
103. Mackell SM. Vaccinations for the pediatric traveler. Clin Infect Dis 2003; 37: 508-516.
104. Infectious diseases of potential risk for travelers. International Travel and Health. World Health Organization, 2010: 53-76. Available at (accessed May 2011).
105. Puthanakit T, Aurpibul L, Yoksan S, Sirisanthana T, Sirisanthana V. Japanese encephalitis vaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy. Vaccine 2007; 25: 8257-8261.
106. Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis 2008; 47: 401-409.
107. Borrow R, Balmer P, Roper M. Module 3: tetanus update. The Immunological basis for immunization series. World Health Organization 2006.
108. Scheifele D, Ochnio J. Module 2: diphtheria update. The Immunological basis for immunization series. World Health Organization 2009.
109. Moss WJ, Scott S. Module 7: measles update. The Immunological basis for immunization series. World Health Organization 2009.
110. Best M, Reef S. Module 11: rubella. The Immunological basis for immunization series. World Health Organisation 2008.
111. Borrow R, Balmer P. Module 15: meningococcal disease. The Immunological basis for immunization series. World Health Organization 2010.
112. Goldblatt D, Assari T. Module 9: haemophilus influenzae type b. The Immunological basis for immunization series. World Health Organization 2007.
113. Kayhty H, Nurkka A, Soininen A, Vakevainen M. Module 12: pneumococcal vaccines. The Immunological basis for immunization series. World Health Organization 2009.
114. Lange CG, Lederman MM, Medvik K etal. Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection. AIDS 2003; 17: 2015-2023.
115. Jacobsen MC, Thiebaut R, Fisher C etal. Pediatric human immunodeficiency virus infection and circulating IgD+ memory B cells. J Infect Dis 2008; 198: 481-485.
116. Ghosh S, Feyen O, Jebran AF etal. Memory B-cell function in HIV-infected children - decreased memory B cells despite ART. Pediatr Res 2009; 66: 185-190.
117. Urschel S, Ramos J, Mellado M etal. Withdrawal of Pneumocystis jirovecii prophylaxis in HIV-infected children under highly active antiretroviral therapy. AIDS 2005; 19: 2103-2108.